Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo

Clinical Therapeutics

Volumn 22, Issue 1, 2000, Pages 128-139

  Mathias, Susan D ^a,f   Colwell, Hilary H ^b   Miller, Dave P ^a   Moreland, Larry W ^c   Buatti, Mary ^d   Wanke, Lee ^e  

^a Lewin Group   (United States)

^b Natl Alliance of Breast Carcer Org   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d WYETH AYERST RESEARCH   (United States)

^e AMGEN INC   (United States)

^f Lewin Group   (United States)

Author keywords

Clinical trial; Etanercept; Functional status; Quality of life; Rheumatoid arthritis

Indexed keywords

ETANERCEPT; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 0033974505     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)87984-9     Document Type: Article

References (28)

1. 1. Grossman JM, Brahn E. Rheumatoid arthritis: Current clinical and research directions. J Women's Health. 1997;6:627-638.
2. 2. Abdel-Nasser AM, Rasker JJ, Valkenburg HA. Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Semin Arthritis Rheum. 1997; 27:123-140.
3. 3. Drosos AA, Alamanos I, Voulgari PV, et al. Epidemiology of adult rheumatoid arthritis in northwest Greece 1987-1995. J Rheumatol. 1997;24:2129-2133.
4. 4. Lipsky PE. Rheumatoid arthritis. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, eds. Harrison's Principles of Internal Medicine. 14th ed. New York: McGraw-Hill, 1998:1880-1888.
5. 5. Bendtsen P, Hörnquist JO. Change and status in quality of life in patients with rheumatoid arthritis. Qual Life Res. 1992; 1:296-305.
6. 6. Mason JH, Weener JL, Gertman PM, Meenan RF. Health status in chronic disease: A comparative study of rheumatoid arthritis. J Rheumatol. 1983;10:763-768.
7. 7. Sullivan S, Swims M. Rheumatoid arthritis: Focus on appropriate drug therapy. Am J Managed Care. 1998;4:900-910.
8. 8. Liang MH, Cullen KE, Larson MG. Measuring function and health status in rheumatic disease clinical trials. Clin Rheum Dis. 1983;9:531-539.
9. 9. Bombardier C, Ware J, Russell IJ, et al. Auranofin therapy and quality of life in patients with rheumatoid arthritis: Results of a multicenter trial. Am J Med. 1986; 81:565-578.
10. 10. Cheah SY, Clark C, Goldberg A, et al. Outcome measures, pooled index and quality of life instruments in rheumatoid arthritis. J Clin Pharm Ther. 1996;21:297-316.
11. 11. Fries JF, Ramey DR. "Arthritis specific" global health analog scales assess "generic" health related quality-of-life in patients with rheumatoid arthritis. J Rheumatol. 1997;24:1697-1702.
12. 12. Bendtsen P, Åkerlind I, Hörnquist JO. Assessment of quality of life in rheumatoid arthritis: Methods and implications. Pharmacoeconomics. 1994;5:286-298.
13. 13. Tugwell P, Bombardier C, Buchanan WW, et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires. Arch Intern Med. 1994;150:59-62.
14. 14. Bell MJ, Bombardier C, Tugwell P. Measurement of functional status, quality of life, and utility in rheumatoid arthritis. Arthritis Rheum. 1990;33:591-601.
15. 15. Fries JF, Spitz PW, Craines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-145.
16. 16. Jette AM. Functional status index: Reliability of a chronic disease evaluation instrument. Arch Phys Med Rehabil. 1980; 61:395-401.
17. 17. Staff of the Benjamin Rose Hospital. Multidisciplinary studies of illness in aged persons: III. Prognostic indices in fracture of hip. J Chronic Dis. 1960;11:445-455.
18. 18. Cella DF, Tulsky DS. Measuring quality of life today: Methodological aspects. Oncology. 1990;4:29-38.
19. 19. Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Status Survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
20. 20. Tuttleman M, Pillemer SR, Tilley BC, et al. A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. J Rheumatol. 1997;24:1910-1915.
21. 21. Jensen MP, Karoly P. Self-report scales and procedures for assessing pain in adults. In: Turk DC, Melzack M, eds. Handbook of Pain Assessments. New York: Guilford Press; 1992:35-151.
22. 22. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999;130:478-486.
23. 23. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
24. 24. Hochberg MC, Chang RW, Dwosh I, et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992;35:498-502.
25. 25. Hawley DJ, Wolfe F. Sensitivity to change of the health assessment questionnaire (HAQ) and other clinical and health status measures in rheumatoid arthritis: Results of short-term clinical trials and observational studies versus long-term observational studies. Arthritis Care Res. 1992;5:130-136.
26. 26. Gardiner PV, Sykes HR, Hassey GA, Walker DJ. An evaluation of the Health Assessment Questionnaire in long-term longitudinal follow-up of disability in rheumatoid arthritis. Br J Rheumatol. 1993;32:724-728.
27. 27. Kramer CY. Extension of multiple range tests to group means with unequal numbers of replications. Biometrics. 1956; 12:309-310.
28. 28. Strand V, Tugwell P, Claire B, et al. Function and health-related quality of life: Results from a randomized, controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum. 1999;42:1870-1878.